Chad (Charles) DePue

NEW: NY’s OCM has decided to transition to Metrc for their seed-to-sale tracking system. This comes after the partnership between Metrc and BioTrack, BioTrack of course was the tech company initially given the seed-to-sale contract in New York. Things to keep in mind as per https://lnkd.in/g_gunAbG: • Licensees who were sending data via the BioTrack NY STS API can now stop. • All licensees are still required to maintain an electronic, real-time inventory tracking system. • Metrc UIDs will cost $0.10, and any BioTrack tags previously purchased will be credited. • Third-party integrators will not be charged to transition from BioTrack’s API to Metrc’s API. • Labs will send testing data to Metrc under the new system. • Until Metrc goes live, transfers must use paper manifests, and licensees should keep historical data in their own systems. • OCM and Metrc will provide updates on API access, sandbox testing, training, and tags in the coming months. • Operators are advised to continue to submit inventory/sales reports to the Office via the portal. • They are aiming to help operators go live with Metrc in early 2026 Distru is a validated third party software integrator with BioTrack in NY, and we are committed to working with Metrc as OCM figures out what next steps are in the coming months. #NYCannabis #Metrc #SeedToSale #Compliance #CannabisTech #Distru

38

3 Comments

Founders are often optimistic about growth. Sometimes, that confidence leads to funding ideas that don't fully pan out. Royalty-based growth capital is structured to limit downside risk compared to traditional venture-backed paths. Vik Thapar of Cypress Growth Capital explains that, even if outcomes fall short of early expectations, founders often still exit with meaningful results because they retain the majority of ownership. 🎙️ Tune into the Private Equity Value Creation Podcast: https://lnkd.in/gxkEsH3Z 👇🏽 Find Us Here https://lnkd.in/gTdPMk8P #privateequity #privateequitypodcast #privateequityvaluecreation

8

Seth Levine nailed it! The concentration problem isn't just a GP pain point... it's choking innovation. When capital pools around the same 20 funds, emerging managers and founders get shut out. Love that he's using his platform to call this out. Foundry has backed 50+ emerging managers. That's the diversification the ecosystem needs. This is exactly why Carta exists — making capital allocation visible and accessible. Capital Evolution hits at exactly the right moment. Thanks for having us Daniel Dart. Team Carta loves the community of FUTURE TITANS you have built 🚀

41

6 Comments

i don't think most people have priced in the fact that codegen is now trivial. the bottlenecks are shifting upstream -- why build, what to build -- and, importantly for us, downstream -- whether what's built holds up in the real world. no software will ever be perfect. bugs happen in production. new corner cases uncovered. reality wins. so the differentiator going forward is designing systems that expect failure, then learn from it. when something breaks, it should be detected, root-caused, and fixed -- fast. and the system should remember the issue so that it's more resilient in the future. anti-fragility will be the new baseline.

9

1 Comment